← Back to headlines
HUTCHMED Initiates Phase III Trial for HMPL-760 in Lymphoma Patients
HUTCHMED has commenced a Phase III clinical trial in China for its drug HMPL-760, targeting patients with relapsed/refractory diffuse large B-cell lymphoma.
23 Mar, 00:00 — 23 Mar, 00:00
